Literature DB >> 18559481

Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease.

Carl R Walkley1, Rameez Qudsi, Vijay G Sankaran, Jennifer A Perry, Monica Gostissa, Sanford I Roth, Stephen J Rodda, Erin Snay, Patricia Dunning, Frederic H Fahey, Frederick W Alt, Andrew P McMahon, Stuart H Orkin.   

Abstract

Osteosarcoma is the most common primary malignant tumor of bone. Analysis of familial cancer syndromes and sporadic cases has strongly implicated both p53 and pRb in its pathogenesis; however, the relative contribution of these mutations to the initiation of osteosarcoma is unclear. We describe here the generation and characterization of a genetically engineered mouse model in which all animals develop short latency malignant osteosarcoma. The genetically engineered mouse model is based on osteoblast-restricted deletion of p53 and pRb. Osteosarcoma development is dependent on loss of p53 and potentiated by loss of pRb, revealing a dominance of p53 mutation in the development of osteosarcoma. The model reproduces many of the defining features of human osteosarcoma including cytogenetic complexity and comparable gene expression signatures, histology, and metastatic behavior. Using a novel in silico methodology termed cytogenetic region enrichment analysis, we demonstrate high conservation of gene expression changes between murine osteosarcoma and known cytogentically rearranged loci from human osteosarcoma. Due to the strong similarity between murine osteosarcoma and human osteosarcoma in this model, this should provide a valuable platform for addressing the molecular genetics of osteosarcoma and for developing novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18559481      PMCID: PMC2428063          DOI: 10.1101/gad.1656808

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  79 in total

Review 1.  Regulation of osteoblast formation and function.

Authors:  J E Aubin
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

Review 2.  Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors.

Authors:  Avery A Sandberg; Julia A Bridge
Journal:  Cancer Genet Cytogenet       Date:  2003-08

3.  Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors.

Authors:  Stephen J Rodda; Andrew P McMahon
Journal:  Development       Date:  2006-07-19       Impact factor: 6.868

4.  Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

Authors:  Paul A Meyers; Cindy L Schwartz; Mark Krailo; Eugenie S Kleinerman; Donna Betcher; Mark L Bernstein; Ernest Conrad; William Ferguson; Mark Gebhardt; Allen M Goorin; Michael B Harris; John Healey; Andrew Huvos; Michael Link; Joseph Montebello; Helen Nadel; Michael Nieder; Judith Sato; Gene Siegal; Michael Weiner; Robert Wells; Lester Wold; Richard Womer; Holcombe Grier
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

5.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Authors:  J Jonkers; R Meuwissen; H van der Gulden; H Peterse; M van der Valk; A Berns
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

6.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

7.  Genetically engineered models have advantages over xenografts for preclinical studies.

Authors:  Oren J Becher; Eric C Holland
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

8.  Mutation spectrum of the retinoblastoma gene in osteosarcomas.

Authors:  B Wadayama; J Toguchida; T Shimizu; K Ishizaki; M S Sasaki; Y Kotoura; T Yamamuro
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

9.  Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry.

Authors:  Julien Sage; Abigail L Miller; Pedro A Pérez-Mancera; Julianne M Wysocki; Tyler Jacks
Journal:  Nature       Date:  2003-07-10       Impact factor: 49.962

10.  Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling.

Authors:  Christopher J Lengner; Heather A Steinman; James Gagnon; Thomas W Smith; Janet E Henderson; Barbara E Kream; Gary S Stein; Jane B Lian; Stephen N Jones
Journal:  J Cell Biol       Date:  2006-03-13       Impact factor: 10.539

View more
  178 in total

1.  p53 inhibits SP7/Osterix activity in the transcriptional program of osteoblast differentiation.

Authors:  Natalia Artigas; Beatriz Gámez; Mónica Cubillos-Rojas; Cristina Sánchez-de Diego; José Antonio Valer; Gabriel Pons; José Luis Rosa; Francesc Ventura
Journal:  Cell Death Differ       Date:  2017-08-04       Impact factor: 15.828

2.  Decreased body weight in young Osterix-Cre transgenic mice results in delayed cortical bone expansion and accrual.

Authors:  Rachel A Davey; Michele V Clarke; Stephen Sastra; Jarrod P Skinner; Cherie Chiang; Paul H Anderson; Jeffrey D Zajac
Journal:  Transgenic Res       Date:  2011-12-13       Impact factor: 2.788

3.  Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression.

Authors:  Kyle C Kurek; Sara Del Mare; Zaidoun Salah; Suhaib Abdeen; Hussain Sadiq; Suk-Hee Lee; Eugenio Gaudio; Nicola Zanesi; Kevin B Jones; Barry DeYoung; Gail Amir; Mark Gebhardt; Matthew Warman; Gary S Stein; Janet L Stein; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 4.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

Review 5.  A review of the association between osteosarcoma metastasis and protein translation.

Authors:  T S Osborne; C Khanna
Journal:  J Comp Pathol       Date:  2012-01-31       Impact factor: 1.311

Review 6.  The retinoblastoma tumor suppressor and stem cell biology.

Authors:  Julien Sage
Journal:  Genes Dev       Date:  2012-07-01       Impact factor: 11.361

Review 7.  Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality.

Authors:  Frederick Bauzon; Liang Zhu
Journal:  Cell Cycle       Date:  2010-06-01       Impact factor: 4.534

8.  CANCER STEM CELLS IN OSTEOSARCOMA.

Authors:  Lindsay Bashur; Guang Zhou
Journal:  Case Orthop J       Date:  2013

9.  microRNA-363 plays a tumor suppressive role in osteosarcoma by directly targeting MAP2K4.

Authors:  Xueqin Li; Xinsheng Liu; Jun Fang; Huazhuang Li; Jingchun Chen
Journal:  Int J Clin Exp Med       Date:  2015-11-15

10.  Conditional inactivation of p53 in mature B cells promotes generation of nongerminal center-derived B-cell lymphomas.

Authors:  Monica Gostissa; Julia M Bianco; Daniel J Malkin; Jeffery L Kutok; Scott J Rodig; Herbert C Morse; Craig H Bassing; Frederick W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.